Details of the Drug

General Information of Drug (ID: DMTO13J)

Drug Name

Clonazepam

Synonyms

Antelepsin; Antilepsin; Chlonazepam; Cloazepam; Clonazepamum; Clonex; Clonopin; Iktorivil; Kenoket; Klonopin; Landsen; Lktorivil; Lonazep; Melzap; Paxam; Ravotril; Rivatril; Rivoril; Rivotril; Solfidin; Klonopin Rapidly Disintegrating; DF2374250; RO4023; Ro 4023; Ro 54023; Alti-Clonazepam; Clonazepamum [INN-Latin]; Klonopin (TN); Ravotril (TN); Rivatril (TN); Rivotril (TN); Ro 4-8180; Ro 5-4023; Ro-5-4023; Clonazepam (JP15/USP/INN); Clonazepam [USAN:INN:BAN:JAN]; Ro 5-4023/B-7; 1,3-Dihydro-5-(o-chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one; 5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one; 5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one; 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one

Indication

Disease Entry	ICD 11	Status	REF
Absence epilepsy	N.A.	Approved	[1]
Epilepsy	8A60-8A68	Approved	[2]
Panic disorder	6B01	Approved	[1]
Seizure disorder	8A6Z	Phase 2	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Anticonvulsants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

315.71

Logarithm of the Partition Coefficient (xlogp)

2.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 36.4 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 18 mcg/L [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 76-85% [3]
Clearance: The clearance of drug is 55 mL/min []
Elimination: Approximately 50-70% of a clonazepam dose is excreted in the urine and 10-30% is excreted in the feces as metabolites []
Half-life: The concentration or amount of drug in body reduced by one-half in 30 - 40 hours []
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.42126 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.15% [6]
Vd: The volume of distribution (Vd) of drug is 3 L/kg []
Water Solubility: The ability of drug to dissolve in water is measured as 0.1 mg/mL [4]

Chemical Identifiers

Formula: C15H10ClN3O3
IUPAC Name: 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
Canonical SMILES: C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl
InChI: InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
InChIKey: DGBIGWXXNGSACT-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2802
ChEBI ID: CHEBI:3756
CAS Number: 1622-61-3
DrugBank ID: DB01068
TTD ID: D0CP4E
INTEDE ID: DR0351
ACDINA ID: D00140

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gamma-aminobutyric acid receptor (GAR)	TTNJYV2	NOUNIPROTAC	Agonist	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
RNA cytidine acetyltransferase (hALP)	DEZV4AP	NAT10_HUMAN	Substrate	[9]
Oxygen-insensitive NADPH nitroreductase B (nfsB)	DE0QLUZ	NFSB_ECOLI	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Clonazepam

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Clonazepam caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Clonazepam caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Clonazepam caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[13]
-----------

Coadministration of a Drug Treating the Disease Different from Clonazepam (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Altered absorption of Clonazepam due to GI dynamics variation caused by Sodium bicarbonate.	Acidosis [5C73]	[14]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Clonazepam caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Clonazepam and Oliceridine.	Acute pain [MG31]	[16]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Clonazepam due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[15]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Clonazepam due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[15]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Clonazepam caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[17]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Clonazepam caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Clonazepam caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Clonazepam caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[19]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Clonazepam caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Clonazepam and Dihydrocodeine.	Chronic pain [MG30]	[21]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Clonazepam caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[22]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Clonazepam caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[23]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Clonazepam and Esketamine.	Depression [6A70-6A7Z]	[24]
SODIUM CITRATE	DMHPD2Y	Minor	Altered absorption of Clonazepam due to GI dynamics variation caused by SODIUM CITRATE.	Discovery agent [N.A.]	[14]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Clonazepam caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[25]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Clonazepam caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[26]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Clonazepam caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[27]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Clonazepam caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[28]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Clonazepam caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Clonazepam caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Clonazepam caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Clonazepam caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Clonazepam caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Clonazepam caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[34]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Clonazepam caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[35]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Clonazepam caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[36]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Clonazepam caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[15]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Clonazepam caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[37]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Clonazepam caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[15]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Clonazepam caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[38]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Clonazepam caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[39]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Clonazepam caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[15]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Clonazepam and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[40]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Clonazepam and Lasmiditan.	Migraine [8A80]	[41]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Clonazepam caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[42]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Clonazepam and Flibanserin.	Mood disorder [6A60-6E23]	[43]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Clonazepam caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[15]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Clonazepam caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[44]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Clonazepam caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[45]
Teduglutide	DMYOAKS	Moderate	Altered absorption of Clonazepam caused by Teduglutide.	Neonatal malabsorption syndrome [KB89]	[46]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Clonazepam and Levomethadyl Acetate.	Opioid use disorder [6C43]	[21]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Clonazepam caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[47]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Clonazepam and Oxymorphone.	Pain [MG30-MG3Z]	[16]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Clonazepam and Dezocine.	Pain [MG30-MG3Z]	[16]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Clonazepam caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[48]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Clonazepam caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[49]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Clonazepam caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[50]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Clonazepam caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[51]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Clonazepam due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[15]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Clonazepam due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[15]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Clonazepam and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[52]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Clonazepam due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[15]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Clonazepam due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[15]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Clonazepam due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[15]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Clonazepam due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[15]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Clonazepam due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[15]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Clonazepam caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[53]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Clonazepam caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[15]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Clonazepam caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[24]
Armodafinil	DMGB035	Minor	Increased metabolism of Clonazepam caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[54]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Clonazepam caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[55]
Amiodarone	DMUTEX3	Minor	Potentiate the pharmacologic effects by the combination of Clonazepam and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[56]
-----------


⏷ Show the Full List of 63 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Aspartame	E00402	134601	Flavoring agent
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Water	E00035	962	Solvent
Xylitol	E00136	6912	Coating agent; Diluent; Emollient; Flavoring agent; Humectant
--------------------


⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Clonazepam 0.125 mg tablet	0.125 mg	Disintegrating Oral Tablet	Oral
Clonazepam 0.25 mg tablet	0.25 mg	Disintegrating Oral Tablet	Oral
Clonazepam 0.5 mg tablet	0.5 mg	Disintegrating Oral Tablet	Oral
Clonazepam 1 mg tablet	1 mg	Disintegrating Oral Tablet	Oral
Clonazepam 2 mg tablet	2 mg	Disintegrating Oral Tablet	Oral
Clonazepam 0.5 mg tablet	0.5 mg	Oral Tablet	Oral
Clonazepam 1 mg tablet	1 mg	Oral Tablet	Oral
Clonazepam 2 mg tablet	2 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Clonazepam FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6963).
3	Product monograph: Nexstellis (estetrol and drospirenone) oral tablets
4	BDDCS applied to over 900 drugs
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
8	Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.
9	Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5.
10	Characterization of Escherichia coli nitroreductase NfsB in the metabolism of nitrobenzodiazepines. Biochem Pharmacol. 2009 Jul 1;78(1):96-103.
11	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
12	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
13	Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
14	Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
15	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
17	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
18	Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
19	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
20	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
21	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
22	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
23	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
24	Cerner Multum, Inc. "Australian Product Information.".
25	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
26	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
27	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
28	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
29	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
30	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
31	Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
32	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
33	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
34	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
35	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
36	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
37	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
38	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
39	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
40	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
41	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
42	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
43	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
44	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
45	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
46	Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
47	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
48	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
49	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
50	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
51	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
52	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
53	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
54	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
55	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
56	Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]